e-learning
resources
ERJ
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP
Boeck L., Eggimann P., Smyrnios N., Pargger H., Thakkar N., Siegemund M., Marsch S., Rakic J., Tamm M., Stolz D.
Source:
Eur Respir J 2011; 37: 595-603
Journal Issue:
March
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Boeck L., Eggimann P., Smyrnios N., Pargger H., Thakkar N., Siegemund M., Marsch S., Rakic J., Tamm M., Stolz D.. Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP. Eur Respir J 2011; 37: 595-603
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH
Source: ERJ Open Res, 6 (4) 00356-2020; 10.1183/23120541.00356-2020
Year: 2020
Pro-adrenomedullin, pro-atrial natriuretic peptide and procalcitonin levels at admission in patients with community-acquired pneumonia and its correlation with risk scores
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 481s
Year: 2007
Levels of procalcitonin, neopterin, C-reactive protein and pro-atrial natriuretic peptide in patients with community-acquired pneumonia and its kinetic according to the severity and the development of complications
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010
Pro-atrial natriuretic peptide and pro-vasopressin to predict short- and long-term survival in community-acquired pneumonia
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009
Influence of antibiotic pre-treatment on pro-atrial natriuretic peptide in community-acquired pneumonia
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
The role of pro-brain natriuretic peptide and C-reactive protein as prognostic markers in stable COPD
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007
Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism
Source: Eur Respir J 2014; 43: 1669-1677
Year: 2014
Plasma n-terminal pro-brain natriuretic peptide (NT pro-BNP) level in respiratory diseases
Source: Eur Respir J 2003; 22: Suppl. 45, 583s
Year: 2003
The use of plasma n-terminal pro B-type natriuretic peptide (proBNP) concentrations in differential diagnosis of comorbidity pulmonary patients
Source: Annual Congress 2011 - Acute respiratory failure
Year: 2011
Pro-atrial natriuretic peptide to predict short-term and long-term mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
The prognostic value of repeated measurements of N-terminal pro-B-type natriuretic peptide in patients with pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Year: 2010
Prognostic significance of amino-terminal pro-brain natriuretic peptide testing among waitlisted lung transplant candidates
Source: Virtual Congress 2021 – Challenging problems in lung transplantation
Year: 2021
The role of N-terminal pro B-type natriuretic peptide in predicting mortality of community acquired pneumonia
Source: International Congress 2019 – Pneumonia in 2019: antimicrobial resistance, cardiovascular complications and diagnosis
Year: 2019
Diagnostic value of N-terminal pro-brain natriuretic peptide in patients with COPD with chronic hypoxemic respiratory failure.
Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Year: 2020
Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology
Source: Eur Respir J 2012; 39: 1144-1155
Year: 2012
Diagnostic value of N-terminal pro-brain natriuretic peptide levels in pleural effusions of cardiac origin
Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Year: 2010
Brain natriuretic peptide (BNP) levels during acute exacerbations of COPD – a novel biomarker
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008
N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patient with acute exacerbations (AE) of COPD
Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Year: 2008
Brain natriuretic peptide (BNP) determination in patients hospitalized for COPD exacerbation
Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept